Chimerix to stop participation in clinical studies of Ebola drug

(Reuters) - Drug developer Chimerix Inc said it would stop participation in clinical studies of its Ebola drug, brincidofovir, citing a significant decrease in the number new cases for the virus in Liberia. The decision was announced after the company's discussions with the U.S. Food and Drug Administration. Brincidofovir was given to the first Ebola patient diagnosed in the United States, Thomas Eric Duncan, who later succumbed to the infection.



via Health News Headlines - Yahoo News http://ift.tt/167CPeR